Susan Collins actually said...
I think we're in the early innings of what will become an evolving set of tools that many innovator drug companies may engage with to protect their assets, and this runs completely counter to the objectives of competition for biosimilars or for other innovative products.
Context
Highlighting concerns about drug companies using legal strategies to hinder competition.
03/22/2021